INOVIQ Ltd Annual Report 2022

24 INOVIQ Limited Chief Scientific Officer Dr Gregory Rice PhD BSc (Hon) MHA Grad Dip Mgt (appointed 20 September 2021) Dr Greg Rice is an internationally recognised academic and commercial scientist with over 30 years’ expertise and experience in oncology, perinatology, exosome-based research, clinical translational research, IVD development and commercialisation. He has held senior academic appointments, co-founded hospital-based clinical research centres in both oncology and perinatology, and co-founded and led diagnostic companies. He is an award-winning scientist with a strong international profile and clinical research networks. He has published more than 280 peer-reviewed scientific publications and is a regular invited speaker at international conferences. He has held numerous academic leadership positions including at the University of Queensland (UQ), Baker Heart and Diabetes Institute, University of Melbourne, andMonash University. As Director of the UQCentre for Clinical Diagnostics (CCD), he established the Centre, implemented an ISO17025 quality management system, secured NATA accreditation, and established an exosome research facility to evaluate the clinical utility of extracellular vesicles as liquid biopsies, IVDs and therapeutics. Additionally, he was a Founding Director and CSO of diagnostics company HealthLinx Ltd and more recently CEO of Pregnostica SpA. His academic qualifications include a Doctor of Philosophy and Bachelor of Science (First Class Honours) from the University of Western Australia and a Graduate Diploma inManagement andMaster of Health Administration fromRMIT University. Chief Scientific Officer Dr Peter French BSc MSc PhDMBA FRSNSW (appointed 17 August 2020 - resigned 17 August 2021) Dr French is a biotechnology executive and respected scientist with previous CSO, CEO and director experience. Most recently, Dr French provided strategic and scientific consulting services to a number of biotechnology companies. His previous industry roles included being executive director of AusDiagnostics Pty Ltd, Bioxyne Ltd and BCAL Diagnostics, Managing Director of Benitec Biopharma Ltd, and founder and Non-Executive director of Cryosite Ltd (ASX: CTE). Dr French also had a successful academic career as Principal Scientist at the Centre for Immunology, St Vincent’s Hospital and Post‑Doctoral Research Scientist at the Children’s Medical Research Foundation. Chief Operations Officer Mr Carl Stubbings BAppSc (appointed 28 July 2020 - resigned 31 August 2021) Mr Stubbings has considerable experience commercialising diagnostic products. His previous executive roles include Senior Vice President for Panbio USA Ltd, Vice-President of Sales andMarketing for Focus Diagnostics, a subsidiary of Quest Diagnostics and Chief Business Officer at Benitec Biopharma Limited (ASX: BLT, NASDAQ: BNTC). He was previously a Non-Executive Director of Analytica Medical Limited (ASX: ALT) and Sienna Cancer Diagnostics Ltd for which he served as Managing Director fromNovember 2019 until July 2020. REVIEWOF OPERATIONS Information on the operations of the Group during the financial year and up to the date of this report is set out separately in the Annual Report under Review of Operations. LEGAL PROCEEDINGS On 24 February 2021, the Company announced that TonyWalker and former director and Founding Scientist of the Company, Dr Irminger-Finger (Plaintiffs and, together, the Claim), had commenced legal proceedings against the Company in the Supreme Court of Victoria. BARD1 (now INOVIQ) advised that it would defend the proceedings and file a comprehensive defence. On 4 June 2021, the Company announced that it had received from the Plaintiffs particulars, and proposed means of calculation, of their alleged loss and damages relating to the Claim and was reviewing it with its legal advisers. Although the calculations derive a potentially very significant amount of claimed loss and damage by the Plaintiffs, any such claimwill ultimately turn on the evidence and the outcome of the legal proceedings at trial. On 28March 2022, the Company announced that it continues to dispute the basis of the Claim and had filed an amended defence in response to amendments to the Plaintiffs’ statement of claim. The proceeding has been listed for trial in February 2023. Directors’ Report

RkJQdWJsaXNoZXIy MjE2NDg3